

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Weingarten et al. MAR 13 2006
Serial No.: 10/524,462 Group Art Unit: 1624
File Date: October 18, 2005 Examiner: Balasubramanian
For: Pyrimidine Derivatives As Selective COX-2 Inhibitors

Director of the U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Notice of Co-Pending Applications: Applicants wish to notify the Examiner of co-pending patent application
Serial Nos.:

11/165,073 filed June 23, 2005
11/119,653 filed May 2, 2005
10/535,806 filed November 21, 2003
10/527,799 filed March 15, 2005
11/110,118 filed April 20, 2005

The foregoing patent applications and granted patents have different inventive entities but are all commonly assigned.

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

- ☒ Copies of the references are enclosed: References 8-15
☐ Copies of the references were submitted in parent application _____ (37 CFR 1.98(d))
☐ A copy of the International Search Report which issued on International Application No. _____ is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

- A. ☐ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

- ☐ The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

- B. ☒ The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:

- (1) a final action under § 1.113 or
(2) a notice of allowance under § 1.311, whichever occurs first.

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

- ☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).

- C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- ☐ The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.

☒ Please charge any required fees to Deposit Account No.07-1392.

☐ A duplicate copy of this paper is attached.

Respectfully Submitted,



J. Scott Young

Registration No. 45,582

Date: 9 Nov 2006

GlaxoSmithKline


Corporate Intellectual Property

5 Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

Telephone: (919) 483-8160

Facsimile: (919) 483-7988

| | | | | | | | |
|---|----|--|-------------------------|---|------------------------|---------------------------------|-----------------------------------|
| FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT | | | | ATTORNEY DOCKET NO. PG4894USW | | SERIAL NO. 10/524,462 | |
|  | | | | APPLICANT: Weingarten et al. | | | |
| | | | | FILING DATE: 10/18/05 | | GROUP 1615 | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| Examiner Initials | | Patent Number | Issue Date | Name | Class | Subclass | Filing Date If Appropriate |
| | 1 | 6,451,794 | Sept. 17, 2002 | Beswick et al. | | | |
| | 2 | 6,498,166 | Dec. 24, 2002 | Campbell et al. | | | |
| | 3 | 6,756,498 | June 29, 2004 | Fitzgerald et al. | | | |
| | 4 | 6,759,413 | July 6, 2004 | Mangel et al. | | | |
| | 5 | 6,803,463 | Oct. 12, 2004 | Mathews et al. | | | |
| | 6 | 6,831,097 | Dec. 14, 2004 | Beswick et al. | | | |
| | 7 | 6,861,249 | Mar. 1, 2005 | Kent | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| Continue on page _____ | | | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | |
| | | Document Number | Publication Date | Country | Class | Subclass | Translation Yes No |
| | 8 | WO 00/26216 | May 11, 2000 | WIPO | | | |
| | 9 | WO 03/14091 | Feb. 20, 2003 | WIPO | | | |
| | 10 | WO 03/77920 | Sept. 25, 2003 | WIPO | | | |
| | 11 | WO 04/18452 | Mar. 4, 2003 | WIPO | | | |
| | 12 | WO 04/24691 | Mar. 25, 2004 | WIPO | | | |
| | 13 | WO 04/48344 | June 10, 2004 | WIPO | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| Continue on page _____ | | | | | | | |
| OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.) | | | | | | | |
| | 14 | Stanghellini et al. "Risk Indicators of Delayed Gastric Emptying of Solids in Patients with Functional Dyspepsia." Gastroenterology, 110(4), 1986, pgs 1036-1042 | | | | | |
| | 15 | Casanova, B., et al. "A Critical Review of the Current Pathogenesis of Multiple Sclerosis and Possible Future Trends." PubMed Abstract (Rev. Neurol. 28(9), May 1999, pgs 909-915. | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| Continue on page _____ | | | | | | | |
| EXAMINER | | | | | DATE CONSIDERED | | |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant. | | | | | | | |